Skip to main content

Zenapax Side Effects

Generic name: daclizumab

Medically reviewed by Drugs.com. Last updated on Aug 9, 2024.

Note: This document provides detailed information about Zenapax Side Effects associated with daclizumab. Some dosage forms listed on this page may not apply specifically to the brand name Zenapax.

Applies to daclizumab: intravenous solution.

Important warnings This medicine can cause some serious health issues

Intravenous route (solution)

Only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe daclizumab, and they should have complete information requisite for the follow-up of the patient.

Daclizumab should only be administered by healthcare personnel trained in the administration of the drug who have available adequate laboratory and supportive medical resources.

Serious side effects of Zenapax

Along with its needed effects, daclizumab (the active ingredient contained in Zenapax) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking daclizumab:

Less common

  • chest pain
  • coughing
  • dizziness
  • fever
  • nausea
  • rapid heart rate
  • red, tender, and oozing skin at incision
  • shortness of breath
  • swelling of the feet or lower legs
  • trembling or shaking of the hands or feet
  • vomiting
  • weakness

Rare

  • frequent urination

Other side effects of Zenapax

Some side effects of daclizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For healthcare professionals

Applies to daclizumab: intravenous solution, subcutaneous solution.

Cardiovascular

Dermatologic

Gastrointestinal

Hematologic

Hypersensitivity

Respiratory

Psychiatric

Other

Hepatic

Immunologic

References

1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

2. Cerner Multum, Inc. "Australian Product Information."

3. (2016) "Product Information. Zinbryta (daclizumab)." AbbVie US LLC

Frequently asked questions

More about Zenapax (daclizumab)

Patient resources

Other brands

Zinbryta

Professional resources

Other brands

Zinbryta

Related treatment guides

Further information

Zenapax side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.